All Oncology News

Natalie S. Callander, MD, discusses the intriguing approaches in both the frontline and relapsed/refractory settings, including trials with antibody-drug conjugates.

Enfortumab vedotin significantly prolonged survival as compared with standard chemotherapy in patients with locally advanced or metastatic urothelial carcinoma or bladder cancer, who had previously received platinum-based treatment and a PD-1–PD-L1 inhibitor.

Although a majority of pancreatic cancer cells are highly dependent on endogenous biosynthesis of cholesterol, new research from investigators at Fox Chase Cancer Center has demonstrated that some more aggressive pancreatic cancers are completely independent of this process.

Binod Dhakal, MD, discusses the potential impact of ide-cel, orva-cel, and cilta-cel in multiple myeloma therapy.

Joleen M. Hubbard, MD, discusses identifying disease progression in patients with colorectal cancer.

Feburary 23, 2021 — The addition of the anti-CD20 monoclonal antibody ublituximab to ibrutinib led to a statistically higher overall response rate over ibrutinib alone with acceptable safety in patients with relapsed/refractory, high-risk, chronic lymphocytic leukemia.

February 23, 2021 - The first patient in a first-in-human phase 1 study has been dosed with DS-6000, a novel CDH6-directed antibody-drug conjugate.

February 23, 2021 - AbbVie and Caribou Biosciences, Inc have entered into a collaboration and license agreement for the research and development of chimeric antigen receptory T-cell therapeutics.

Anne Chiang, MD, PhD, has been named Deputy Chief Medical Officer and Chief Integration Officer at Smilow Cancer Hospital.

Constantine S. Tam, MD, discusses the key findings of the phase 3 SYMPATICO study and where this combination might fit best into a sequence of therapies.

February 23, 2021 - The FDA has approved the PD-L1 IHC 22C3 pharmDx assay, developed by Agilent Technologies Inc, for expanded use in patients with non–small cell lung cancer.

Jason Zhu, MD, discusses several approaches under exploration in the treatment of patients with previously treated, locally advanced, or metastatic urothelial carcinoma.

ADP-A2M4CD8, a novel T-cell therapy, is being investigated in a range of tumor types that express MAGEA4, an antigen expressed in solid tumors that investigators say represents a promising target for cellular immunotherapy.

Gary J. Schiller, MD, discusses data from the 2020 ASH Annual Meeting and Exposition and the role of transplant in chronic myeloid leukemia.

February 22, 2021 - The FDA has granted a fast track designation to the DNA-mediated interleukin-12 immunotherapy GEN-1 for use in the treatment of patients with advanced ovarian cancer.

Timothy M. Schmidt, MD, discusses the safety and efficacy of teclistamab in patients with multiple myeloma.

February 22, 2021 - The FDA has granted priority review to a supplemental new drug application for ruxolitinib for use in adult and pediatric patients aged 12 years and older with steroid-refractory chronic graft-versus-host disease.

February 22, 2021 - The FDA has approved cemiplimab-rwlc monotherapy for use in the frontline treatment of patients with advanced non–small cell lung cancer with a PD-L1 expression level of 50% or higher.

Sara A. Hurvitz, MD, discusses the potential integration of oral taxanes into the treatment paradigm of patients with metastatic breast cancer.

Claud N. Grigg, MD, highlights different frontline combination regimens that are improving outcomes for patients with metastatic renal cell carcinoma.

A recent wave of drug approvals for treating prostate cancer in earlier disease states, coupled with genomic advances, may help pave the way for a shift toward handling the malignancy as a chronic condition.

AstraZeneca has voluntarily withdrawn durvalumab from the US market for the treatment of adult patients with locally advanced or metastatic bladder cancer.

Davey B. Daniel, MD, discusses key immunotherapy trials in advanced non–small cell lung cancer and explains how the results can be extrapolated to clinical practice.

Although chemotherapy remains the cornerstone of treatment in pancreatic ductal adenocarcinoma, the field has begun to carve out more personalized approaches evidenced by the POLO trial.

When one is dealing with the topic of cancer, its treatment and consequences, language that clinicians and members of the cancer research community use may have an even greater impact.

February 19, 2021 - The National Comprehensive Cancer Network has issued guidelines for the management of children with a rare type of kidney cancer referred to as Wilms Tumor, or nephroblastoma.

February 19, 2021 - Multitarget stool DNA test Cologuard could present a potential noninvasive screening method for colorectal cancer, as it has demonstrated high specificity among average-risk patients aged 45 to 49 years.

Patients with metastatic renal cell carcinoma have a new frontline treatment alternative following FDA approval of the combination of nivolumab plus cabozantinib combination.

Christos Vaklavas, MD, discusses the progress that has been made in metastatic HR-positive, HER2-negative breast cancer and potential pathways forward for therapeutic sequencing.

A reduced frequency of maintenance vincristine and dexamethasone led to a 5-year overall survival rate of 98.6% and improved quality of life in pediatric patients with newly diagnosed, standard-risk B-cell acute lymphoblastic leukemia.